EPISODE · Sep 16, 2025 · 9 MIN
Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.
from BiotechTV - News · host BiotechTV
CEO Nicklas Westerholm walks us through the condition, which is an X-chromosome linked rare disease that affects men, and he describes how the launch is going in Europe, and plans for an FDA meeting.
Embed this episode
Ready to play
Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.
0:00
9:01
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 9 minutes long.
When was this BiotechTV - News episode published?
This episode was published on September 16, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!